| Primary |
| Pyrexia |
52.7% |
| Drug Use For Unknown Indication |
11.0% |
| Teething |
9.6% |
| Product Used For Unknown Indication |
6.9% |
| Ear Infection |
6.1% |
| Asthma |
3.5% |
| Nasopharyngitis |
2.5% |
| Injection |
1.6% |
| Ill-defined Disorder |
1.2% |
| Irritability |
1.2% |
| Vitamin Supplementation |
1.0% |
| Malaise |
0.6% |
| Urinary Tract Infection |
0.6% |
| Hypersensitivity |
0.4% |
| Influenza Like Illness |
0.4% |
| Allergy Prophylaxis |
0.2% |
| Discomfort |
0.2% |
| Labyrinthitis |
0.2% |
| Pain |
0.2% |
|
| Product Quality Issue |
47.3% |
| Pyrexia |
10.0% |
| Vomiting |
7.5% |
| Transmission Of An Infectious Agent Via A Medicinal Product |
5.5% |
| Weight Decreased |
3.5% |
| Wrong Drug Administered |
2.5% |
| Drug Ineffective |
2.0% |
| Hypersensitivity |
2.0% |
| Product Contamination Physical |
2.0% |
| Somnolence |
2.0% |
| Upper Respiratory Tract Infection |
2.0% |
| Urinary Tract Infection |
2.0% |
| Coma |
1.5% |
| Death |
1.5% |
| Febrile Convulsion |
1.5% |
| Red Blood Cell Sedimentation Rate Increased |
1.5% |
| Respiratory Arrest |
1.5% |
| Salmonellosis |
1.5% |
| Transfusion |
1.5% |
| Urticaria |
1.5% |
|
| Secondary |
| Pyrexia |
46.8% |
| Teething |
14.7% |
| Drug Use For Unknown Indication |
13.4% |
| Ear Infection |
8.2% |
| Product Used For Unknown Indication |
4.8% |
| Malaise |
2.5% |
| Pharyngitis |
2.3% |
| Asthma |
1.5% |
| Nasopharyngitis |
1.3% |
| Bacterial Infection |
0.7% |
| Injection |
0.7% |
| Analgesic Therapy |
0.5% |
| Hypersensitivity |
0.5% |
| Irritability |
0.5% |
| Infection |
0.4% |
| Vitamin Supplementation |
0.4% |
| Rhinorrhoea |
0.3% |
| Urinary Tract Infection |
0.3% |
| Labyrinthitis |
0.2% |
| Viral Pharyngitis |
0.2% |
|
| Product Quality Issue |
52.4% |
| Pyrexia |
8.9% |
| Vomiting |
8.6% |
| Transmission Of An Infectious Agent Via A Medicinal Product |
5.1% |
| Respiratory Arrest |
3.8% |
| Weight Decreased |
3.8% |
| Wrong Drug Administered |
3.5% |
| Skin Reaction |
1.6% |
| Streptococcal Infection |
1.6% |
| Product Contamination Physical |
1.1% |
| Respiratory Disorder |
1.1% |
| Somnolence |
1.1% |
| Upper Respiratory Tract Infection |
1.1% |
| Urinary Tract Infection |
1.1% |
| White Blood Cell Count Increased |
1.1% |
| Coma |
0.8% |
| Death |
0.8% |
| Febrile Convulsion |
0.8% |
| Red Blood Cell Sedimentation Rate Increased |
0.8% |
| Skin Discolouration |
0.8% |
|
| Concomitant |
| Pyrexia |
66.7% |
| Tonsillitis |
33.3% |
|
| Transmission Of An Infectious Agent Via A Medicinal Product |
100.0% |
|
